Chronic Lymphocytic Leukemia

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

Paolo Ghia, MD, PhD, discusses the rationale for conducting an OS analysis of fixed-duration ibrutinib plus venetoclax in patients with CLL.

Allison Winter, MD, emphasizes the importance of carefully evaluating treatment history in patients with Richter transformation from CLL.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

BTK mutations occurred at low rates in patients with CLL who had disease progression after receiving zanubrutinib or ibrutinib in the phase 3 ALPINE study.

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta analysis of BTK inhibitors in relapsed/refractory CLL.

The EMA’s CHMP has recommended the approval for acalabrutinib/venetoclax with or without obinutuzumab in untreated CLL.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

China’s NMPA has approved orelabrutinib for the first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.

A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R CLL.

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

Francisco J. Hernandez-Ilizaliturri, MD, discusses the rationale behind assessing immunologic changes seen with venetoclax treatment in patients with CLL.

Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.

Zanubrutinib plus venetoclax and obinutuzumab was well tolerated—aside from COVID-19–related toxicities—in patients with relapsed/refractory CLL.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

On February 13, 2025, a select group of experts in chronic lymphocytic leukemia (CLL) participated in a virtual workshop to discuss the evolving treatment landscape of CLL and discussed subjects ranging from treatment of newly diagnosed patients to therapies for those relapsed/refractory (R/R) disease. Moderated by Alexey V. Danilov, MD, PhD, the discussion covered insights into emerging treatment approaches, novel therapeutic strategies, and sequencing of available therapies to optimize patient outcomes. This article was supported in part by Eli Lilly. Content independently developed and published by OncLive.